# Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer

> **NCT00193271** · PHASE2 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 30 (—)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Estramustine

## Key facts

- **NCT ID:** NCT00193271
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-08
- **Primary completion:** 2007-05
- **Final completion:** 2007-05
- **Target enrollment:** 30 (—)
- **Last updated:** 2011-05-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00193271

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00193271, "Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00193271. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*